Standalone Device Strategy Demands Early FDA, EMA Engagement
Genentech, TÜV SÜD and FDA CBER advisors mapped regulatory pathways for standalone devices paired with drugs at the AFDO/RAPS Combination Products Summit in Baltimore.
TAG V-9816 · 579 words on the filing

Summary of findings
- Panel spoke at the AFDO/RAPS Combination Products Summit in Baltimore on Tuesday.
- CECP under MDR Article 54 is the only EMA–notified body interface, applying to certain Class III and IIb devices.
- In the EU, a standalone device requires notified body certification before EMA starts drug review.
- FDA's request for designation tool helps identify the lead center and testing requirements.
- General device clearance requires compatibility data with at least one approved drug, validated for dose, rate, route and configuration.
Pharma companies adding standalone medical devices to their drug portfolios must engage regulators early and master two parallel review systems — that was the core message from a panel at the AFDO/RAPS Combination Products Summit in Baltimore on Tuesday.
Porsche Sanders, regulatory group director at Genentech, said pharma firms increasingly adopt standalone physical devices to differentiate therapies. The shift forces them out of a drug-centric mindset: they must understand device regulatory pathways and take on legal manufacturer responsibilities.
Which pathway, which lead center?
"Early alignment is really important here, and this is where the request for designation can be a good tool that the FDA has," Sanders said. Early engagement helps manufacturers pick the right FDA lead center, pin down testing requirements and align multiple offices within a center on data expectations.
In the US, manufacturers should weigh user and stakeholder alignment, technical considerations and labeling strategy. In Europe, they face an added layer: notified bodies require a quality management system conformity assessment for a CE mark, on top of EMA's drug review.
"Some of us come from pharmaceutical companies that don't have a ton of standalone device expertise," Sanders said. "That's why it is important to have early engagement within your cross-functional teams for what your clinical evaluation should look like, because you may need device endpoints in your clinical study."
How do EMA and notified bodies interact?
Jara Benke, senior product specialist at TÜV SÜD, laid out the EU mechanics: a standalone device means two independent reviews. The notified body certifies the device first; only then can EMA start the drug assessment.
"There is no planned interaction between EMA and the notified body during the device certification or the drug approval," Benke said.
The single exception is the clinical evaluation consultation procedure (CECP), the only interface between the two regulators, triggered at the end of device certification for certain high-risk Class III and Class IIb devices under MDR Article 54. An independent expert panel reviews clinical evidence, novel device features, clinical procedures, and the benefit-risk balance. A changed intended purpose can also trigger the CECP postmarket — though a change in indications alone doesn't.
What does FDA expect from drug and device makers?
Andrea Gray, a biomedical engineering advisor at CBER, addressed combination products where drug and device makers are separate entities. "The drug sponsor needs to ensure that the drug quality is preserved when it's used with that specific device, and the device manufacturer needs to make sure that the device performs as intended to deliver that specific drug," she said.
That requires:
- Robust quality agreements covering change notification, data sharing and issue coordination, including postmarket safety information and root cause investigations.
- Aligned regulatory timelines for separate applications, because the product labels depend on each other.
- Drug-device compatibility data showing neither component degrades the other.
Gray also flagged the one-way labeling approach, where a drug references a specific device but the device carries general labeling. A device maker pursuing general clearance must demonstrate compatibility with at least one approved drug, validated for dose, rate, route and configuration per that drug's labeling.
Novel delivery systems likely lack drug-delivery experience and would need a pharma partner for co-development, Gray said. For off-the-shelf devices, sponsors must stay within the cleared intended use; repackaging or re-sterilization demands bridging data, and commercialization may require the device maker to update labeling or build a custom device.
via Regulatory Focus (Google News) (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- K-6477
- P-6323
- P-4283
- E-6328
- E-4696